Open Access

Role of STX6 as a prognostic factor associated with immune infiltration in hepatocellular carcinoma

  • Authors:
    • Yang Zhang
    • Leyan Li
    • Yi Tu
    • Zongfeng Feng
    • Yong Li
    • Jianbo Xiong
  • View Affiliations

  • Published online on: September 5, 2022     https://doi.org/10.3892/ol.2022.13491
  • Article Number: 371
  • Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Syntaxin 6 (STX6), a soluble N‑ethylmaleimide-sensitive factor‑activating receptor protein, has formed an increasing part of cancer research. However, to the best of our knowledge, the role of STX6 in hepatocellular carcinoma (HCC) is still unclear. In the present study, data from multiple bioinformatics databases, including The Cancer Genome Atlas, Gene Expression Omnibus, Kaplan‑Meier plotter, Tumor Immune Estimation Resource (TIMER) and Gene Expression Profiling Integrative Analysis (GEPIA2), and immunohistochemistry (IHC) were utilized to assess the role of STX6 in HCC. The results demonstrated that STX6 expression was upregulated in HCC tissues compared with normal tissues. STX6 expression was significantly associated with tumor size, Edmondson grade and α‑fetoprotein (AFP) level. Furthermore, survival analysis demonstrated that high STX6 expression was significantly associated with poor prognosis in patients with HCC. Furthermore, assessment of the immune infiltrates demonstrated that CD163 expression was positively correlated with the STX6 level when analyzed using the TIMER and GEPIA2 databases. IHC results further demonstrated this association. Furthermore, compared with the typically used AFP, STX6 could have an improved diagnostic value in the diagnosis of HCC. In conclusion, STX6 expression was not only positively associated with poor prognosis but may also be involved in the immune inflammatory reaction in HCC. STX6 may become a potential therapeutic and diagnosis maker for patients with HCC.
View Figures
View References

Related Articles

Journal Cover

October-2022
Volume 24 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhang Y, Li L, Tu Y, Feng Z, Li Y and Xiong J: Role of STX6 as a prognostic factor associated with immune infiltration in hepatocellular carcinoma. Oncol Lett 24: 371, 2022
APA
Zhang, Y., Li, L., Tu, Y., Feng, Z., Li, Y., & Xiong, J. (2022). Role of STX6 as a prognostic factor associated with immune infiltration in hepatocellular carcinoma. Oncology Letters, 24, 371. https://doi.org/10.3892/ol.2022.13491
MLA
Zhang, Y., Li, L., Tu, Y., Feng, Z., Li, Y., Xiong, J."Role of STX6 as a prognostic factor associated with immune infiltration in hepatocellular carcinoma". Oncology Letters 24.4 (2022): 371.
Chicago
Zhang, Y., Li, L., Tu, Y., Feng, Z., Li, Y., Xiong, J."Role of STX6 as a prognostic factor associated with immune infiltration in hepatocellular carcinoma". Oncology Letters 24, no. 4 (2022): 371. https://doi.org/10.3892/ol.2022.13491